Related Experiment Video
Updated: Jun 16, 2026
10:58
Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
Published on: July 18, 2016
Clinical Case of Primary Ovarian Osteosarcoma
O Manzhura1,2, L Zakhartseva2,3, Ye Maystrenko2
1Shupyk National Healthcare University of Ukraine, Kyiv, Ukraine.
Experimental Oncology
|June 15, 2026
Summary
This case study details an extremely rare primary ovarian osteosarcoma (OS) in a 70-year-old woman. Further research is crucial due to diagnostic challenges and lack of treatment consensus for this rare ovarian cancer.
Area of Science:
- Oncology
- Gynecologic Oncology
- Pathology
Background:
- Primary ovarian osteosarcoma (OS) is an exceptionally rare malignancy.
- This tumor type is not currently classified in the 2022 World Health Organization (WHO) classification of genital tumors.
- Diagnosis and treatment strategies for ovarian OS remain challenging due to limited data.
Purpose of the Study:
- To report a rare clinical case of primary ovarian osteosarcoma in a postmenopausal woman.
- To discuss the diagnostic criteria for primary ovarian OS.
- To emphasize the need for further research into the characteristics and management of this rare tumor.
Main Methods:
- Case report of a 70-year-old female patient diagnosed with primary ovarian OS.
- Review of diagnostic criteria for ovarian osteosarcoma.
- Description of patient's treatment course including chemotherapy and follow-up.
- Observation of tumor progression and metastatic disease.
Main Results:
- A 70-year-old woman presented with primary ovarian osteosarcoma.
- The patient received chemotherapy and was monitored for 27 months.
- Tumor progression with peritoneal metastasis was observed.
- The rarity and diagnostic difficulty of ovarian OS were highlighted.
Conclusions:
- Primary ovarian osteosarcoma, though rare and unclassified by WHO, requires careful diagnosis and further investigation.
- Accumulating data on tumor features and treatment response is essential for improving patient outcomes.
- This case underscores the importance of continued research in rare gynecologic malignancies.
